These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 26215797

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation.
    Inagaki J, Kodama Y, Fukano R, Noguchi M, Okamura J.
    Pediatr Transplant; 2015 Sep; 19(6):652-8. PubMed ID: 26103520
    [Abstract] [Full Text] [Related]

  • 3. Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus.
    Dvorak CC, Callard E, Agarwal R.
    Bone Marrow Transplant; 2006 Aug; 38(3):253-4. PubMed ID: 16785867
    [No Abstract] [Full Text] [Related]

  • 4. Maximizing the benefits of mycophenolate mofetil as graft-versus-host disease prophylaxis.
    Hamilton BK, Kalaycio M.
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1869-70. PubMed ID: 25065905
    [No Abstract] [Full Text] [Related]

  • 5. Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease.
    Busca A, Locatelli F, Marmont F, Audisio E, Falda M.
    Haematologica; 2003 Jul; 88(7):837-9. PubMed ID: 12857569
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient.
    Basara N, Blau WI, Kiehl MG, Römer E, Rudolphi M, Bischoff M, Kirsten D, Sanchez H, Günzelmann S, Fauser AA.
    Transplant Proc; 1998 Dec; 30(8):4087-9. PubMed ID: 9865306
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Benefits of mycophenolate mofetil for refractory graft-versus-host disease].
    Mori M, Muroi K, Matsuyama T, Oka S, Ono Y, Yamamoto C, Uesawa M, Okabe H, Matsu H, Tatara R, Kikuchi Y, Fujiwara S, Kikuchi S, Sato K, Ueda M, Toshima M, Ozaki K, Takatoku M, Nagai T, Ozawa K.
    Rinsho Ketsueki; 2007 Aug; 48(8):624-31. PubMed ID: 17867298
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease.
    Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, Mayer J.
    Ann Hematol; 2005 Oct; 84(10):681-5. PubMed ID: 16001244
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan.
    Iida M, Fukuda T, Uchida N, Murata M, Aotsuka N, Minagawa K, Oohashi K, Fukushima K, Kondo T, Eto T, Miyamoto T, Morishima Y, Nagamura T, Atsuta Y, Suzuki R.
    Clin Transplant; 2014 Sep; 28(9):980-9. PubMed ID: 24943923
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.